Following regulatory changes, CSL Behring is now able to offer plasma fractionation and purification services to Italy’s public healthcare sector for the first time. General manager Oliver Schmitt discusses the added value and savings CSL Behring can offer in this service segment and the benefits its newest generation of innovative therapies can bring to patients.
Given your 16 years’ experience working in the plasma derivatives industry, what would you identify as the defining characteristics of the Italian plasma market?
We are excited to finally be able to offer the Italian regions access to our products at a great price level, which is crucial in times of limited resources.
